HER2 Vaccine for Locally Advanced Breast Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorPravin T.P Kaumaya
About this trial
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Eligibility criteria
Qualifiers
≥ 18 years old at the time of informed consent
Ability to provide written informed consent and HIPAA authorization CTO-IUSCC-0864
Histologically confirmed HER2 positive breast cancer
Any Estrogen Receptor/Progesterone Receptor status is allowed.
Disqualifiers
Any distant disease recurrence.
Patients with active malignancy other than breast cancer. Note: Patients with prior malignancies without recurrence after standard treatment will not be excluded.
Patients receiving or planned to receive adjuvant CDK4/6 inhibitor therapy
Patients who are {MVF-HER-2(266-296) and MVF-HER-2 (597-626)} immediate hypersensitivity skin test positive.
Trial design
Treatments tested in this trial
- HER2 Vaccine
Treatment groups
36 Participants
are divided into 1 treatment groupLocations
1Indiana University Melvin & Bren Simon Comprehensive Cancer Center46202, IndianapolisIndiana, United States
Sponsors and collaborators
Pravin T.P Kaumaya
Lead sponsor
Indiana University
Sponsor institution
Source ClinicalTrials.gov